ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Vertex Pharmaceuticals said on Monday it will not continue development of its experimental non-opioid painkiller as a solo ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

Discover key insights from Vertex, Inc.'s Q2 2025 earnings: solid revenue growth, macro challenges, and a focus on e-invoicing opportunities.

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Google's Veo 3 Fast model is available in Vertex AI alongside the larger Veo 3 model. The post highlights some ways users can enjoy both AI video generators, such as more storytel ...

Jon Rahm shares why he's "always confident" in his game ahead of The Open Championship, before Live From examines how he is rounding into form in recent majors and how his career has evolved since his ...